This study investigates unresectable pancreatic cancer. It explores the use of the NanoKnife Irreversible Electroporation System, which is an off-label application for this condition.
The study evaluates the safety and effectiveness of the NanoKnife System in managing pain associated with the condition. It also looks into the quality of life after the procedure.
- Who can participate: Participants must be 18 years or older with locally advanced unresectable disease following standard chemotherapy or radiotherapy and should not have received chemotherapy or radiotherapy within 5 weeks prior to treatment with the NanoKnife IRE System.
- Study details: Participants will undergo a procedure using the NanoKnife System. The study will monitor safety and pain levels.